Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
December 19, 2024 16:15 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine.
Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
December 13, 2024 08:30 ET
|
Medicenna Therapeutics Corp.
Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive mouse...
Precede Biosciences Presents a Novel ER Transcriptional Dependency Index at SABCS 2024 Designed to Further Inform Use of Endocrine Therapy from a Simple Blood Test
December 12, 2024 08:00 ET
|
Precede Biosciences, Inc.
Precede Bio’s ER dependency index (PERDI) tests for both ER dependent and ER independent mechanisms of cancer growth, addressing an important unmet need in the field todayThere are approximately...
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
December 10, 2024 09:05 ET
|
Arvinas Inc.
– Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6...
New MammoCAT Advanced Mammography System Offers Substantial Improvements in Dense Breast Imaging
December 10, 2024 08:38 ET
|
Fischer Imaging
MammoCAT Mammography System lessens need for painful breast compression, improves image quality in dense breast tissue, and decreases radiation dose.
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
December 09, 2024 16:05 ET
|
Myriad Genetics, Inc.
Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium.
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research
December 09, 2024 08:15 ET
|
Atossa Therapeutics, Inc.
SEATTLE, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas...
Breast Cancer Liquid Biopsy Market is Estimated to be USD 2,731.02 Million by 2034, With a CAGR of 8.5% | PMR
November 28, 2024 07:32 ET
|
Polaris Market Research & Consulting LLP
New York, USA, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Market Overview: The global breast cancer liquid biopsy market size was USD 1,209.01 million in 2024, estimated at USD 1,310.56 million in 2025, and...
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
November 27, 2024 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
November 25, 2024 17:35 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented at the 2024 San...